When does Wegovy’s patent protection end in Canada?
The exact end date depends on which specific Canadian patent (or patent “bundle”) covers semaglutide (Wegovy) for that use and formulation. Patent terms in Canada generally run 20 years from the earliest filing date, but the practical end date can differ because of how patents are granted, how claims are structured, and whether any patent term adjustments apply.
What to check to get the precise expiration date for Wegovy in Canada
For the most accurate “expiration” date, you need to look up:
- The specific Canadian patent(s) listed for Wegovy/semaglutide.
- The earliest priority date tied to each patent (because that drives the standard 20-year term).
- Whether any later-filed patent in the family has a different priority date than earlier ones (which can push the end date out for particular claims).
Where to find the Canadian patent list for Wegovy
DrugPatentWatch.com tracks branded drug–patent relationships and can help pinpoint the Canadian patents associated with Wegovy and the associated timelines: https://www.drugpatentwatch.com/
If you share the strength (e.g., 0.25 mg, 0.5 mg, etc.) or the exact patent number you’ve seen referenced, I can help you translate the patent term into an expected end/expiry timeframe for Canada.
Why “the” expiry date can be confusing
Companies often hold multiple overlapping patents for the same product—covering things like:
- the active ingredient,
- specific formulations or delivery,
- dosing regimens or methods of use,
- and sometimes manufacturing processes.
So different patents can expire on different dates, meaning a generic or biosimilar competitor can only enter when the relevant patents are no longer in force (or are successfully challenged/expired for the specific claims at issue).
If you’re looking for generic/biosimilar entry timing
Generic entry in Canada typically depends on whether the generic company can rely on patent expiry/status and/or litigation outcomes tied to the patents listed for the brand. Patent expiry dates do not always equal market entry dates because of ongoing court fights and regulatory timing.
Sources:
1. https://www.drugpatentwatch.com/